Parnax Lab Limited (BOM:506128)

India flag India · Delayed Price · Currency is INR
134.05
-1.55 (-1.14%)
At close: Jun 18, 2026
Market Cap1.54B +36.4%
Revenue (ttm)2.49B +32.4%
Net Income117.77M +2.2%
EPS10.27 +2.4%
Shares Out 11.49M
PE Ratio13.05
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume6,228
Open137.00
Previous Close135.60
Day's Range133.55 - 138.45
52-Week Range96.25 - 182.00
Beta0.04
AnalystsStrong Buy
Price Target51.00 (-61.95%)
Earnings DateMay 28, 2026

About Parnax Lab

Parnax Lab Limited engages in the manufacture and export of pharmaceutical formulations in India and internationally. The company offers pharmaceutical products in the form of liquids, ointments, gels, creams, tablets, and capsules; cosmetic products; herbal products; and nutraceutical products. It also provides Oral Formulations, such as cough expectorants, antacids, antihistamines, multi-vitamins, enzyme preparations, pediatric formulations, formulations for geriatrics, highly viscous products, and suspensions. In addition, the company provid... [Read more]

Industry Pharmaceutical Preparations
Founded 1982
Employees 12
Stock Exchange Bombay Stock Exchange
Ticker Symbol 506128
Full Company Profile

Financial Performance

In fiscal year 2026, Parnax Lab's revenue was 2.49 billion, an increase of 32.36% compared to the previous year's 1.88 billion. Earnings were 117.77 million, an increase of 2.24%.

Financial Statements